{"id":351286,"date":"2025-08-25T20:43:31","date_gmt":"2025-08-25T20:43:31","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-cg-oncology\/"},"modified":"2025-08-25T20:43:31","modified_gmt":"2025-08-25T20:43:31","slug":"how-to-buy-cg-oncology","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/","title":{"rendered":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m","h1_source":{"label":"H1","type":"text","formatted_value":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m"},"description":"Bu umut vadeden biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile CG Oncology (CGON) hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Bu umut vadeden biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile CG Oncology (CGON) hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Mesane kanseri tedavisinde devrim yaratabilecek bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. CG Oncology, analistlerin heyecanla takip etti\u011fi \u00e7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7larla FDA onay\u0131na do\u011fru h\u0131zla ilerliyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kendi kendini anlatan verilerle onkolojide potansiyel bir oyun de\u011fi\u015ftirici.","intro_source":{"label":"Intro","type":"text","formatted_value":"Mesane kanseri tedavisinde devrim yaratabilecek bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. CG Oncology, analistlerin heyecanla takip etti\u011fi \u00e7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7larla FDA onay\u0131na do\u011fru h\u0131zla ilerliyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kendi kendini anlatan verilerle onkolojide potansiyel bir oyun de\u011fi\u015ftirici."},"body_html":"<h2>\ud83d\udcc8 CG Oncology Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla CG Oncology, Inc. (CGON) NASDAQ'ta <strong>26,915 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu fiyat, Nisan 2025'teki 15,59 $'l\u0131k dipten ola\u011fan\u00fcst\u00fc bir toparlanmay\u0131 temsil ediyor\u2014yat\u0131r\u0131mc\u0131 g\u00fcveninin bu klinik a\u015famadaki biyoteknoloji m\u00fccevherine geri d\u00f6nd\u00fc\u011f\u00fcn\u00fc g\u00f6steren \u015fa\u015f\u0131rt\u0131c\u0131 bir <strong>%70 art\u0131\u015f<\/strong>.<\/p> <p><strong>Takviminizde 11 Kas\u0131m 2025 tarihini parlak k\u0131rm\u0131z\u0131 ile i\u015faretleyin.<\/strong> CG Oncology'nin 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131\u011f\u0131 g\u00fcn bu. Tarih g\u00f6steriyor ki bu t\u00fcr olaylar hisse fiyat\u0131n\u0131 dramatik \u015fekilde etkiliyor. 8 A\u011fustos 2025'teki son kazan\u00e7 raporu, 0,05 $ EPS sapmas\u0131 (-0,54 $ ger\u00e7ekle\u015fen vs -0,49 $ beklenen) nedeniyle hisse fiyat\u0131nda tepki g\u00f6rd\u00fc ancak temel klinik ilerleme yat\u0131r\u0131mc\u0131lar\u0131 iyimser tuttu.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>Son kazan\u00e7 tepkilerine bak\u0131ld\u0131\u011f\u0131nda net bir desen ortaya \u00e7\u0131k\u0131yor: bu hisse finansal g\u00fcncellemeler etraf\u0131nda kararl\u0131l\u0131kla hareket ediyor:<\/p> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>\u00d6nceki Fiyat<\/th> <th>Sonraki Fiyat<\/th> <th>De\u011fi\u015fim<\/th> <\/tr> <\/thead> <tbody> <tr> <td>8 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>24,51 $<\/td> <td>25,07 $<\/td> <td>+%2,3<\/td> <\/tr> <tr> <td>12 Kas 2024<\/td> <td>3. \u00c7eyrek 2024<\/td> <td>39,69 $<\/td> <td>36,98 $<\/td> <td>-%6,8<\/td> <\/tr> <tr> <td>8 A\u011fu 2024<\/td> <td>2. \u00c7eyrek 2024<\/td> <td>31,06 $<\/td> <td>33,24 $<\/td> <td>+%7,0<\/td> <\/tr> <tr> <td>9 May 2024<\/td> <td>1. \u00c7eyrek 2024<\/td> <td>32,43 $<\/td> <td>30,02 $<\/td> <td>-%7,4<\/td> <\/tr> <\/tbody> <\/table> <p>Desen? <strong>Olumlu s\u00fcrprizler momentum yarat\u0131rken, olumsuz sonu\u00e7lar ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur<\/strong>\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in m\u00fckemmel.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\ude80 6 Ayl\u0131k Fiyat Yolculu\u011fu: Panikten Umuda<\/h2> <p>CGON'un \u015eubat 2025'ten bu yana yolculu\u011fu bir biyoteknoloji gerilim filmi gibi:<\/p> <p><strong>\u015eubat 2025<\/strong>: Olumlu klinik veriler sonras\u0131 yakla\u015f\u0131k 28 $ seviyesinde i\u015flem g\u00f6rd\u00fc<br\/> <strong>Nisan 2025<\/strong>: Nakit yak\u0131m\u0131 endi\u015feleri nedeniyle panik ya\u015fanarak 15,59 $'a d\u00fc\u015ft\u00fc<br\/> <strong>Haziran 2025<\/strong>: G\u00fcvenin geri d\u00f6nmesiyle 22 $ band\u0131na istikrarl\u0131 t\u0131rman\u0131\u015f<br\/> <strong>A\u011fustos 2025<\/strong>: Yenilenen iyimserlikle 26 $ engelini a\u015ft\u0131<\/p> <p>Bu <strong>Nisan diplerinden %72 toparlanma<\/strong>, hissenin dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Volatilite? Kesinlikle sinir bozucu. F\u0131rsat? Sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel olarak hayat de\u011fi\u015ftiren.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilir:<\/p> <p><strong>2025 Hedefi<\/strong>: 62-79 $ aral\u0131\u011f\u0131 (mevcut fiyattan %136-%193 y\u00fckseli\u015f)<br\/> <strong>2026 Projeksiyonu<\/strong>: 80-100 $ (FDA onay ba\u015far\u0131s\u0131na ba\u011fl\u0131)<br\/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 120-150 $ (ticarile\u015fme \u00f6l\u00e7eklendirmesi)<br\/> <strong>2030 Vizyonu<\/strong>: 200 $+ (piyasa liderli\u011fi kurulmu\u015f)<\/p> <p><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Klinik veriler \u00e7ok \u015fey anlat\u0131yor ve FDA tasar\u0131mlar\u0131 (Breakthrough Therapy + Fast Track) h\u0131zland\u0131r\u0131lm\u0131\u015f onay potansiyelini g\u00f6steriyor.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Sat\u0131n Almadan \u00d6nce Bilin<\/h2> <h3>Ba\u015fl\u0131ca Riskler:<\/h3> <ul> <li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: T\u00fcm yat\u0131r\u0131m cretostimogene onay\u0131na ba\u011fl\u0131<\/li> <li><strong>Nakit Yak\u0131m\u0131 Krizi<\/strong>: Gelir olmadan y\u0131ll\u0131k 82 milyon $ nakit yak\u0131m\u0131<\/li> <li><strong>Reg\u00fclasyon Gecikmeleri<\/strong>: FDA onay zaman \u00e7izelgesi belirsizlikleri<\/li> <li><strong>Biyoteknoloji Volatilitesi<\/strong>: Bu sekt\u00f6rde %50+ fiyat dalgalanmalar\u0131 normal<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Sinyaller:<\/h3> <ul> <li><strong>%75,7 tam yan\u0131t oran\u0131<\/strong> Faz 3 denemelerinde<\/li> <li><strong>%46 yan\u0131t dayan\u0131kl\u0131l\u0131\u011f\u0131 12 ayda<\/strong>\u2014s\u0131n\u0131f\u0131n\u0131n en iyisi veri<\/li> <li><strong>742 milyon $ nakit pozisyonu<\/strong> operasyonlar\u0131 2028'e kadar finanse ediyor<\/li> <li><strong>FDA Breakthrough Designation<\/strong> inceleme s\u00fcrecini h\u0131zland\u0131r\u0131yor<\/li> <\/ul> <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Kazan\u00e7 tarihleri civar\u0131nda par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Ani klinik aksiliklere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: FDA kararlar\u0131 ve deneme sonu\u00e7lar\u0131 bu hisseyi hareket ettirir<\/li> <\/ol> <p>Mizahi deneyimli tavsiye: \"CGON ticareti yapmak, t\u0131bbi drama izlemek gibidir\u2014senaryo s\u00fcrprizleri i\u00e7in g\u00fc\u00e7l\u00fc sinirlere ihtiyac\u0131n\u0131z var ama sezon finali muhte\u015fem olabilir!\"<\/p> <h2>\u2705 CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Platformunuzu Se\u00e7in<\/td> <td>NASDAQ hisseleri ve kesirli paylar sunmas\u0131na dikkat edin<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td> <td>Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"CGON\" Aray\u0131n<\/td> <td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Limit Emri Verin<\/td> <td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Emir detaylar\u0131n\u0131 y\u00fcr\u00fctmeden \u00f6nce \u00e7ift kontrol edin<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131?<\/h2> <p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, CGON'un risk-getiri profiline m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> stratejileri b\u00fcy\u00fck sermaye riski olmadan test etmenizi sa\u011flar<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> hesap olu\u015fturduktan dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flaman\u0131z\u0131 sa\u011flar<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> k\u00e2r almaya haz\u0131r oldu\u011funuzda esneklik sunar<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, \u00f6zellikle tek seansta %10 dalgalanabilen hisselerle u\u011fra\u015f\u0131rken biyoteknoloji volatilitesini y\u00f6netmeyi kolayla\u015ft\u0131r\u0131r.<\/p> <h2>\ud83e\uddec 2025'te CG Oncology: Mesane Kanserinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2> <p>CG Oncology, mesane kanseri tedavisini d\u00f6n\u00fc\u015ft\u00fcrme e\u015fi\u011finde duruyor. Cretostimogene, %75,7'lik e\u015fi benzeri g\u00f6r\u00fclmemi\u015f yan\u0131t oranlar\u0131 ve 28 ay\u0131 a\u015fan dayan\u0131kl\u0131l\u0131k g\u00f6stererek, bu sadece ba\u015fka bir biyoteknoloji hikayesi de\u011fil\u2014potansiyel olarak t\u0131bbi tarihin yaz\u0131ld\u0131\u011f\u0131 bir an.<\/p> <p>\u015eirketin 1,98 milyar $ piyasa de\u011feri, hem muazzam f\u0131rsat\u0131 hem de ge\u00e7 a\u015fama ila\u00e7 geli\u015ftirmedeki \u00f6nemli riski yans\u0131t\u0131yor. CGON'u \u00f6zellikle \u00e7ekici k\u0131lan, operasyonlar\u0131 2028'e kadar finanse eden <strong>742 milyon $ nakit rezervi<\/strong> ile d\u00fczenleyici onay ve ilk ticarile\u015fme i\u00e7in geni\u015f bir zaman dilimi sa\u011flamas\u0131d\u0131r.<\/p> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: CG Oncology'nin \u00f6nc\u00fc ilac\u0131 cretostimogene, onkolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza att\u0131\u2014ayn\u0131 anda FDA Breakthrough Therapy VE Fast Track tasar\u0131mlar\u0131n\u0131 alarak potansiyel onay yolunda h\u0131zl\u0131 \u015feride girdi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 CG Oncology Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla CG Oncology, Inc. (CGON) NASDAQ&#8217;ta <strong>26,915 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu fiyat, Nisan 2025&#8217;teki 15,59 $&#8217;l\u0131k dipten ola\u011fan\u00fcst\u00fc bir toparlanmay\u0131 temsil ediyor\u2014yat\u0131r\u0131mc\u0131 g\u00fcveninin bu klinik a\u015famadaki biyoteknoloji m\u00fccevherine geri d\u00f6nd\u00fc\u011f\u00fcn\u00fc g\u00f6steren \u015fa\u015f\u0131rt\u0131c\u0131 bir <strong>%70 art\u0131\u015f<\/strong>.<\/p>\n<p><strong>Takviminizde 11 Kas\u0131m 2025 tarihini parlak k\u0131rm\u0131z\u0131 ile i\u015faretleyin.<\/strong> CG Oncology&#8217;nin 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131\u011f\u0131 g\u00fcn bu. Tarih g\u00f6steriyor ki bu t\u00fcr olaylar hisse fiyat\u0131n\u0131 dramatik \u015fekilde etkiliyor. 8 A\u011fustos 2025&#8217;teki son kazan\u00e7 raporu, 0,05 $ EPS sapmas\u0131 (-0,54 $ ger\u00e7ekle\u015fen vs -0,49 $ beklenen) nedeniyle hisse fiyat\u0131nda tepki g\u00f6rd\u00fc ancak temel klinik ilerleme yat\u0131r\u0131mc\u0131lar\u0131 iyimser tuttu.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>Son kazan\u00e7 tepkilerine bak\u0131ld\u0131\u011f\u0131nda net bir desen ortaya \u00e7\u0131k\u0131yor: bu hisse finansal g\u00fcncellemeler etraf\u0131nda kararl\u0131l\u0131kla hareket ediyor:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>\u00d6nceki Fiyat<\/th>\n<th>Sonraki Fiyat<\/th>\n<th>De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>8 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>24,51 $<\/td>\n<td>25,07 $<\/td>\n<td>+%2,3<\/td>\n<\/tr>\n<tr>\n<td>12 Kas 2024<\/td>\n<td>3. \u00c7eyrek 2024<\/td>\n<td>39,69 $<\/td>\n<td>36,98 $<\/td>\n<td>-%6,8<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>31,06 $<\/td>\n<td>33,24 $<\/td>\n<td>+%7,0<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>1. \u00c7eyrek 2024<\/td>\n<td>32,43 $<\/td>\n<td>30,02 $<\/td>\n<td>-%7,4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen? <strong>Olumlu s\u00fcrprizler momentum yarat\u0131rken, olumsuz sonu\u00e7lar ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur<\/strong>\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in m\u00fckemmel.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\ude80 6 Ayl\u0131k Fiyat Yolculu\u011fu: Panikten Umuda<\/h2>\n<p>CGON&#8217;un \u015eubat 2025&#8217;ten bu yana yolculu\u011fu bir biyoteknoloji gerilim filmi gibi:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: Olumlu klinik veriler sonras\u0131 yakla\u015f\u0131k 28 $ seviyesinde i\u015flem g\u00f6rd\u00fc<br \/> <strong>Nisan 2025<\/strong>: Nakit yak\u0131m\u0131 endi\u015feleri nedeniyle panik ya\u015fanarak 15,59 $&#8217;a d\u00fc\u015ft\u00fc<br \/> <strong>Haziran 2025<\/strong>: G\u00fcvenin geri d\u00f6nmesiyle 22 $ band\u0131na istikrarl\u0131 t\u0131rman\u0131\u015f<br \/> <strong>A\u011fustos 2025<\/strong>: Yenilenen iyimserlikle 26 $ engelini a\u015ft\u0131<\/p>\n<p>Bu <strong>Nisan diplerinden %72 toparlanma<\/strong>, hissenin dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Volatilite? Kesinlikle sinir bozucu. F\u0131rsat? Sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel olarak hayat de\u011fi\u015ftiren.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilir:<\/p>\n<p><strong>2025 Hedefi<\/strong>: 62-79 $ aral\u0131\u011f\u0131 (mevcut fiyattan %136-%193 y\u00fckseli\u015f)<br \/> <strong>2026 Projeksiyonu<\/strong>: 80-100 $ (FDA onay ba\u015far\u0131s\u0131na ba\u011fl\u0131)<br \/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 120-150 $ (ticarile\u015fme \u00f6l\u00e7eklendirmesi)<br \/> <strong>2030 Vizyonu<\/strong>: 200 $+ (piyasa liderli\u011fi kurulmu\u015f)<\/p>\n<p><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Klinik veriler \u00e7ok \u015fey anlat\u0131yor ve FDA tasar\u0131mlar\u0131 (Breakthrough Therapy + Fast Track) h\u0131zland\u0131r\u0131lm\u0131\u015f onay potansiyelini g\u00f6steriyor.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Sat\u0131n Almadan \u00d6nce Bilin<\/h2>\n<h3>Ba\u015fl\u0131ca Riskler:<\/h3>\n<ul>\n<li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: T\u00fcm yat\u0131r\u0131m cretostimogene onay\u0131na ba\u011fl\u0131<\/li>\n<li><strong>Nakit Yak\u0131m\u0131 Krizi<\/strong>: Gelir olmadan y\u0131ll\u0131k 82 milyon $ nakit yak\u0131m\u0131<\/li>\n<li><strong>Reg\u00fclasyon Gecikmeleri<\/strong>: FDA onay zaman \u00e7izelgesi belirsizlikleri<\/li>\n<li><strong>Biyoteknoloji Volatilitesi<\/strong>: Bu sekt\u00f6rde %50+ fiyat dalgalanmalar\u0131 normal<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller:<\/h3>\n<ul>\n<li><strong>%75,7 tam yan\u0131t oran\u0131<\/strong> Faz 3 denemelerinde<\/li>\n<li><strong>%46 yan\u0131t dayan\u0131kl\u0131l\u0131\u011f\u0131 12 ayda<\/strong>\u2014s\u0131n\u0131f\u0131n\u0131n en iyisi veri<\/li>\n<li><strong>742 milyon $ nakit pozisyonu<\/strong> operasyonlar\u0131 2028&#8217;e kadar finanse ediyor<\/li>\n<li><strong>FDA Breakthrough Designation<\/strong> inceleme s\u00fcrecini h\u0131zland\u0131r\u0131yor<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Kazan\u00e7 tarihleri civar\u0131nda par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Ani klinik aksiliklere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: FDA kararlar\u0131 ve deneme sonu\u00e7lar\u0131 bu hisseyi hareket ettirir<\/li>\n<\/ol>\n<p>Mizahi deneyimli tavsiye: &#8220;CGON ticareti yapmak, t\u0131bbi drama izlemek gibidir\u2014senaryo s\u00fcrprizleri i\u00e7in g\u00fc\u00e7l\u00fc sinirlere ihtiyac\u0131n\u0131z var ama sezon finali muhte\u015fem olabilir!&#8221;<\/p>\n<h2>\u2705 CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>NASDAQ hisseleri ve kesirli paylar sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CGON&#8221; Aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit Emri Verin<\/td>\n<td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 y\u00fcr\u00fctmeden \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131?<\/h2>\n<p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, CGON&#8217;un risk-getiri profiline m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> stratejileri b\u00fcy\u00fck sermaye riski olmadan test etmenizi sa\u011flar<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> hesap olu\u015fturduktan dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flaman\u0131z\u0131 sa\u011flar<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> k\u00e2r almaya haz\u0131r oldu\u011funuzda esneklik sunar<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, \u00f6zellikle tek seansta %10 dalgalanabilen hisselerle u\u011fra\u015f\u0131rken biyoteknoloji volatilitesini y\u00f6netmeyi kolayla\u015ft\u0131r\u0131r.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te CG Oncology: Mesane Kanserinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2>\n<p>CG Oncology, mesane kanseri tedavisini d\u00f6n\u00fc\u015ft\u00fcrme e\u015fi\u011finde duruyor. Cretostimogene, %75,7&#8217;lik e\u015fi benzeri g\u00f6r\u00fclmemi\u015f yan\u0131t oranlar\u0131 ve 28 ay\u0131 a\u015fan dayan\u0131kl\u0131l\u0131k g\u00f6stererek, bu sadece ba\u015fka bir biyoteknoloji hikayesi de\u011fil\u2014potansiyel olarak t\u0131bbi tarihin yaz\u0131ld\u0131\u011f\u0131 bir an.<\/p>\n<p>\u015eirketin 1,98 milyar $ piyasa de\u011feri, hem muazzam f\u0131rsat\u0131 hem de ge\u00e7 a\u015fama ila\u00e7 geli\u015ftirmedeki \u00f6nemli riski yans\u0131t\u0131yor. CGON&#8217;u \u00f6zellikle \u00e7ekici k\u0131lan, operasyonlar\u0131 2028&#8217;e kadar finanse eden <strong>742 milyon $ nakit rezervi<\/strong> ile d\u00fczenleyici onay ve ilk ticarile\u015fme i\u00e7in geni\u015f bir zaman dilimi sa\u011flamas\u0131d\u0131r.<\/p>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: CG Oncology&#8217;nin \u00f6nc\u00fc ilac\u0131 cretostimogene, onkolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza att\u0131\u2014ayn\u0131 anda FDA Breakthrough Therapy VE Fast Track tasar\u0131mlar\u0131n\u0131 alarak potansiyel onay yolunda h\u0131zl\u0131 \u015feride girdi.<\/p>\n"},"faq":[{"question":"CG Oncology hisseleri nereden al\u0131n\u0131r?","answer":"CG Oncology hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden CGON sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CG Oncology'nin klinik ba\u015far\u0131 \u015fans\u0131 nedir?","answer":"\u015eirketin cretostimogene ilac\u0131 Faz 3 denemelerinde %75,7 tam yan\u0131t oran\u0131 ve 12 ayda %46 yan\u0131t dayan\u0131kl\u0131l\u0131\u011f\u0131 g\u00f6stermi\u015ftir, bu da y\u00fcksek bir klinik ba\u015far\u0131 potansiyeline i\u015faret etmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik ba\u015far\u0131s\u0131zl\u0131k, y\u00fcksek nakit yak\u0131m\u0131, FDA onay s\u00fcre\u00e7lerindeki belirsizlikler ve biyoteknoloji sekt\u00f6r\u00fcndeki y\u00fcksek volatilite bulunmaktad\u0131r."},{"question":"CG Oncology hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 hedef fiyat\u0131 62-79 $ aral\u0131\u011f\u0131nda olup, 2030 y\u0131l\u0131nda 200 $ ve \u00fczeri piyasa liderli\u011fi hedeflenmektedir."},{"question":"Yeni ba\u015flayanlar CG Oncology hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmadan k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve FDA kararlar\u0131 ile klinik geli\u015fmeleri yak\u0131ndan takip edin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"CG Oncology hisseleri nereden al\u0131n\u0131r?","answer":"CG Oncology hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden CGON sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CG Oncology'nin klinik ba\u015far\u0131 \u015fans\u0131 nedir?","answer":"\u015eirketin cretostimogene ilac\u0131 Faz 3 denemelerinde %75,7 tam yan\u0131t oran\u0131 ve 12 ayda %46 yan\u0131t dayan\u0131kl\u0131l\u0131\u011f\u0131 g\u00f6stermi\u015ftir, bu da y\u00fcksek bir klinik ba\u015far\u0131 potansiyeline i\u015faret etmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik ba\u015far\u0131s\u0131zl\u0131k, y\u00fcksek nakit yak\u0131m\u0131, FDA onay s\u00fcre\u00e7lerindeki belirsizlikler ve biyoteknoloji sekt\u00f6r\u00fcndeki y\u00fcksek volatilite bulunmaktad\u0131r."},{"question":"CG Oncology hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 hedef fiyat\u0131 62-79 $ aral\u0131\u011f\u0131nda olup, 2030 y\u0131l\u0131nda 200 $ ve \u00fczeri piyasa liderli\u011fi hedeflenmektedir."},{"question":"Yeni ba\u015flayanlar CG Oncology hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmadan k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve FDA kararlar\u0131 ile klinik geli\u015fmeleri yak\u0131ndan takip edin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:43:31+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m\",\"datePublished\":\"2025-08-25T20:43:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\",\"name\":\"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-25T20:43:31+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/","og_locale":"tr_TR","og_type":"article","og_title":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:43:31+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m","datePublished":"2025-08-25T20:43:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/","name":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r - CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-25T20:43:31+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cg-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"CG Oncology, Inc. (CGON) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CG Oncology, Inc. (CGON) Hissesine Yat\u0131r\u0131m"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351285,"slug":"how-to-buy-cg-oncology","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CG Oncology, Inc. (CGON) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CG Oncology, Inc. (CGON)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cg-oncology\/"},"pt_AA":{"locale":"pt_AA","id":351288,"slug":"how-to-buy-cg-oncology","post_title":"Como comprar a\u00e7\u00f5es da CG Oncology, Inc. (CGON) - Investimento em a\u00e7\u00f5es da CG Oncology, Inc. (CGON)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cg-oncology\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351286"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}